A rare case of incidentally diagnosed pulmonary inflammatory myofibroblastic tumour with dramatic response to crizotinib in a postpartum woman
  • Jojo Yorke
    Department of Internal Medicine, Division of Pulmonary/Critical Care, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
  • Krupa Solanki
    Department of Internal Medicine, Division of Pulmonary/Critical Care, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
  • Vaishnavi Theegala
    Department of Internal Medicine, Division of Pulmonary/Critical Care, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
  • Alok Kumar Sinha
    Department of Pathology, James H. Quillen College of Medicine, East Tennessee State University, Johnson City, USA
  • Don E Asberry
    Department of Pathology, Highlands Pathology, Bristol, USA
  • Adel El Abbassi
    Bristol Regional Medical Center, Bristol, USA

Keywords

Pulmonary inflammatory myofibroblastic tumor, hypertension

Abstract

Introduction: Inflammatory myofibroblastic tumours are rare neoplasms which most commonly affect children and young adults. With an intermediate malignant potential, they are typically detected in the abdomen, lung, mediastinum, head and neck, gastrointestinal tract, and genitourinary tract.

Case description: We describe the case of a 33-year-old postpartum woman incidentally diagnosed with a pulmonary inflammatory myofibroblastic tumour following complaints of poorly controlled hypertension a week after caesarean section. She was ALK-negative and received an ALK inhibitor with complete resolution of the lesion. A ROS1–TFG fusion confirmed the diagnosis of an inflammatory myofibroblastic tumour after CT-guided fine needle aspiration.

Discussion: This case highlights an uncommon presentation posing a diagnostic and therapeutic challenge and the potential treatment option of crizotinib.

VIEW THE ENTIRE ARTICLE

References

  • WHO Classification of Tumours Editorial Board. Soft tissue and bone tumours. In: WHO classification of tumours, 5th ed., vol. 3. Lyon, France: International Agency for Research on Cancer; 2020. https://publications.iarc.fr/588.
  • Khatri A, Agrawal A, Sikachi RR, Mehta D, Sahni S, Meena N. Inflammatory myofibroblastic tumor of the lung. Adv Resp Med 2018;86:27–35. https://doi.org/ 10.5603/ARM.2018.0007.
  • Lee YJ, Jeong JS, Kim SR, Lee YC. Inflammatory myofibroblastic tumor of the lung with multifocal metastases. JTO Clin Res Rep 2020;1:100007. doi: 10.1016/j.jtocrr.2020.100007.
  • Yang F, Zhang W, Han C, Jiang H. A case of pulmonary inflammatory myofibroblastic tumor treated with bronchoscopic therapy plus lobectomy. J Cardiothorac Surg 2021;16:144. https://doi.org/10.1186/s13019-021-01528-5.
  • Comandini D, Catalano F, Grassi M, Pesola G, Bertulli R, Guadagno A, et al. Outstanding response in a patient with ROS1-rearranged inflammatory myofibroblastic tumor of soft tissues treated with crizotinib: case report. Front Oncol 2021;11:658327. doi: 10.3389/fonc.2021.658327.ISSN=2234-943X.
  • Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 2014;371:1963–1971. doi: 10.1056/NEJMoa1406766. PMID: 25264305; PMCID: PMC4264527.
  • Pettinato G, Manivel JC, De Rosa N, Dehner LP. Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations. Am J Clin Pathol 1990;94:538–546. https://doi.org/10.1093/ajcp/94.5.538.
  • Coffin C, Watterson J, Priest J, Dehner L. Extrapulmonary inflammatory myofibroblastic tumor (inflammatory pseudotumor). A clinicopathologic and immunohistochemical study of 84 cases. Am J Surg Pathol 1995;19:859–872.
  • Views: 337
    HTML downloads: 100
    PDF downloads: 346


    Published: 2023-04-06
    Issue: 2023: Vol 10 No 4 (view)


    How to cite:
    1.
    Yorke J, Solanki K, Theegala V, Sinha A, Asberry D, El Abbassi A. A rare case of incidentally diagnosed pulmonary inflammatory myofibroblastic tumour with dramatic response to crizotinib in a postpartum woman. EJCRIM 2023;10 doi:10.12890/2023_003626.